EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study

Andréa Clément de Givry, Pauline Manchon, Marianne Veyri, Julie Delyon, Nausicaa Malissen iD, Caroline Gaudy-Marqueste, Ouidad Zehou, Arnaud Jannic, Emilie Gérard, Nora Kramkimel, Christine Longvert, Eve Maubec und 16 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf419 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2025. Verfasst von Andréa Clément de Givry und 27 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Dermatology, Hôpital Bichat-Claude-Bernard AP-HP, Paris, France. Hauptthemen laut MEDLINE: Skin Neoplasms, Immune Checkpoint Inhibitors, HIV Infections. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People living with HIV (PWH) have an increased risk of developing aggressive skin cancers, yet they have been largely excluded from immune checkpoint inhibitor (ICI) trials. Consequently, evidence on the safety and efficacy of ICIs in this population remains scarce, particularly for the nivolumab plus ipilimumab (NIVO+IPI) combination.

Methods

This multicentre, real-world study included PWH treated with ICIs for melanoma or non-melanoma skin cancers. The objective was to evaluate patient characteristics, treatment management, and clinical outcomes across the different skin cancer types.

Results

Among the 54 patients, 89% were male, and 92.6% had a suppressed HIV viral load. Melanoma was the most frequent tumour (35/54, 64.8%), followed by cutaneous squamous cell carcinoma (12/54, 22.2%), Kaposi sarcoma (4/54, 7.4%), basal cell carcinoma (2/54, 3.7%), and one Merkel cell carcinoma. Anti-PD-1/PD-L1 monotherapy was given as first-line treatment in 81.5% (44/54). Immune-related adverse events (irAEs) occurred in 42.6% (23/54), with a median onset of 43.5 days (IQR, 20.5–126). The maximum toxicity grade was 1/2 in 39% (21/54), grade ≥ 3 in 13% (7/54). Seventeen melanoma patients received NIVO+IPI. Among them, 64.7% (11/17) experienced irAEs, including grade ≥ 3 events in 30% (5/17). Objective response rates were 43% (9/21) in melanoma, 58% (7/12) in cSCC, and 75% (3/4) in Kaposi sarcoma.

Conclusions

PWH treated with ICIs for skin cancer demonstrated favourable outcomes, with a notably reassuring safety profile of NIVO+IPI. These findings support managing well-controlled PWH similarly to the general population and highlight the importance of including this population across all settings of skin cancer trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsImmune Checkpoint InhibitorsHIV InfectionsHumansMaleFemaleMiddle AgedAgedAdultNivolumabMelanomaTreatment Outcome

Stichwörter der Autor:innen

HIVimmune checkpoint inhibitorsimmune-related adverse eventsmelanomanon-melanoma skin cancersafety

Substanzen

Immune Checkpoint InhibitorsNivolumab

Autor:innen und Institutionen

  • Departement of Dermatology, Hôpital Bichat-Claude-Bernard AP-HP, Paris, France.
  • Clinical Investigation Centre, Hôpital Bichat-Claude-Bernard AP-HP, Paris, France.
  • Departement of Medical Oncology, Institut Pierre Louis d'Épidémiologie et de Santé Publique (iPLESP), INSERM, Sorbonne Université, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.
  • Departement of Dermatology, Hôpital Saint-Louis AP-HP, Paris, France.
  • Departement of Dermatology, Hôpital La Timone AP-HM, Marseille, France.
  • Departement of Dermatology, Hôpital Henri Mondor AP-HP, Créteil, France.

ORCID-Profile: Nausicaa Malissen, Marie Boileau, Charlée Nardin, Jade Ghosn, Florence Brunet Possenti

Zitieren

APA

de Givry, A. C., Manchon, P., Veyri, M., Delyon, J., Malissen, N., Gaudy-Marqueste, C., Zehou, O., Jannic, A., Gérard, E., Kramkimel, N., Longvert, C., Maubec, E., Boileau, M., Stoebner, P. E., Montaudié, H., Quéreux, G., L'Orphelin, J. M., Poirier, E., Girard, C., …, & Brunet Possenti, F. (2025). Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study. The Oncologist. https://doi.org/10.1093/oncolo/oyaf419

Vancouver

de Givry AC, Manchon P, Veyri M, Delyon J, Malissen N, Gaudy-Marqueste C, et al. Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study. The Oncologist. 2025. doi:10.1093/oncolo/oyaf419

BibTeX
@article{deGivry2025,
  author = {de Givry, Andréa Clément and Manchon, Pauline and Veyri, Marianne and Delyon, Julie and Malissen, Nausicaa and Gaudy-Marqueste, Caroline and Zehou, Ouidad and Jannic, Arnaud and Gérard, Emilie and Kramkimel, Nora and Longvert, Christine and Maubec, Eve and Boileau, Marie and Stoebner, Pierre-Emmanuel and Montaudié, Henri and Quéreux, Gaëlle and L'Orphelin, Jean-Matthieu and Poirier, Elodie and Girard, Céline and Nardin, Charlée and Mortier, Laurent and Ferré, Valentine-Marie and Descamps, Vincent and Spano, Jean-Philippe and Laouenan, Cédric and Ghosn, Jade and Lebbé, Céleste and Brunet Possenti, Florence},
  title = {Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf419}
}
Kostenlos starten →